Merrimack Pharmaceuticals (MACK) 10-K2023 FY Annual report

Filed: 7 Mar 24, 4:15pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: accessing, accretion, ADC, Additionally, addressed, artificial, automated, back, banking, brought, captioned, certainty, Chancery, commensurate, conjugate, coverage, cybersecurity, dark, denial, Department, disagree, disagreement, disaster, discharge, dissolution, dissolve, dissolving, diverse, education, enabling, encryption, Erroneously, escalate, exceed, expertise, factor, FDIC, function, geolocation, gradually, hardware, hosted, hosting, imposition, inaccurate, incident, inside, intelligence, intestate, intrusion, jurisdiction, lawsuit, learning, lower, machine, mentioned, mitigate, network, organizational, outlined, oversee, patch, penetration, permanent, physical, pipeline, presidential, prioritize, pro, procedure, rata, reach, recovery, relevant, remediate, remote, return, satisfy, segregation, similarly, sized, smaller, software, spring, subset, tabletop, technical, thousand, threat, timeline, unaffiliated, unforeseen, uninsured, unknown, unsettled, vendor, web, wiping

Removed: allocation, assignee, ASU, beginning, Database, execution, FASB, funding, incremental, intraperiod, Label, Les, line, Linkbase, nanoliposome, negotiate, partially, plc, recognition, reimbursed, SAS, satisfactory, Servier, Shire, simultaneously, title, Topic

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

MACK similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in the Registration Statement of Merrimack Pharmaceuticals, Inc. on Form S-3 (No. 333-222093) and Form S-8 (Nos. 333-180996, 333-186370, 333-194313, 333-202346, 333-209745, 333-223577, 333-230084, 333-237155 and 333- 268609) of our report dated March 7, 2024 with respect to our audits of the consolidated financial statements of Merrimack Pharmaceuticals, Inc. as of December 31, 2023 and 2022 and for the years then ended, which report is included in this Annual Report on Form 10-K of Merrimack Pharmaceuticals, Inc. for the year ended December 31, 2023.

/s/ Marcum LLP

Marcum LLP

Boston, Massachusetts

March 7, 2024